BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Jaeger WC, Seeber RM, Eidne KA, Pfleger KD. Molecular determinants of orexin receptor-arrestin-ubiquitin complex formation. Br J Pharmacol 2014;171:364-74. [PMID: 24206104 DOI: 10.1111/bph.12481] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
Number Citing Articles
1 Ayoub MA. Resonance Energy Transfer-Based Approaches to Study GPCRs. Methods Cell Biol 2016;132:255-92. [PMID: 26928548 DOI: 10.1016/bs.mcb.2015.10.008] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
2 Thompson MD, Sakurai T, Rainero I, Maj MC, Kukkonen JP. Orexin Receptor Multimerization versus Functional Interactions: Neuropharmacological Implications for Opioid and Cannabinoid Signalling and Pharmacogenetics. Pharmaceuticals (Basel) 2017;10:E79. [PMID: 28991183 DOI: 10.3390/ph10040079] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 5.0] [Reference Citation Analysis]
3 Johnstone EK, Pfleger KD. Bioluminescence Resonance Energy Transfer Approaches to Discover Bias in GPCR Signaling. Methods Mol Biol 2015;1335:191-204. [PMID: 26260602 DOI: 10.1007/978-1-4939-2914-6_13] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
4 Lessel U, Ferrara M, Heine N, Marelli C, Carrettoni L, Pfau R, Schmidt E, Riether D. Identification of Highly Selective Orexin 1 Receptor Antagonists Driven by Structure-Based Design. J Chem Inf Model 2021;61:5893-905. [PMID: 34817173 DOI: 10.1021/acs.jcim.1c01055] [Reference Citation Analysis]
5 Jaeger WC, Armstrong SP, Hill SJ, Pfleger KD. Biophysical Detection of Diversity and Bias in GPCR Function. Front Endocrinol (Lausanne) 2014;5:26. [PMID: 24634666 DOI: 10.3389/fendo.2014.00026] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 2.5] [Reference Citation Analysis]
6 Jean-Charles PY, Rajiv V, Shenoy SK. Ubiquitin-Related Roles of β-Arrestins in Endocytic Trafficking and Signal Transduction. J Cell Physiol 2016;231:2071-80. [PMID: 26790995 DOI: 10.1002/jcp.25317] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 5.2] [Reference Citation Analysis]
7 Stoddart LA, White CW, Nguyen K, Hill SJ, Pfleger KD. Fluorescence- and bioluminescence-based approaches to study GPCR ligand binding. Br J Pharmacol 2016;173:3028-37. [PMID: 26317175 DOI: 10.1111/bph.13316] [Cited by in Crossref: 66] [Cited by in F6Publishing: 65] [Article Influence: 9.4] [Reference Citation Analysis]
8 Tiulpakov A, White CW, Abhayawardana RS, See HB, Chan AS, Seeber RM, Heng JI, Dedov I, Pavlos NJ, Pfleger KD. Mutations of Vasopressin Receptor 2 Including Novel L312S Have Differential Effects on Trafficking. Mol Endocrinol 2016;30:889-904. [PMID: 27355191 DOI: 10.1210/me.2016-1002] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 4.0] [Reference Citation Analysis]
9 Langmead CJ. From orphans to orexins: an arousing fifteen years: Editorial. Br J Pharmacol 2014;171:281-2. [DOI: 10.1111/bph.12556] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
10 Jean-Charles PY, Freedman NJ, Shenoy SK. Chapter Nine - Cellular Roles of Beta-Arrestins as Substrates and Adaptors of Ubiquitination and Deubiquitination. Prog Mol Biol Transl Sci 2016;141:339-69. [PMID: 27378762 DOI: 10.1016/bs.pmbts.2016.04.003] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
11 Yang Z, Yang F, Zhang D, Liu Z, Lin A, Liu C, Xiao P, Yu X, Sun J. Phosphorylation of G Protein-Coupled Receptors: From the Barcode Hypothesis to the Flute Model. Mol Pharmacol 2017;92:201-10. [DOI: 10.1124/mol.116.107839] [Cited by in Crossref: 63] [Cited by in F6Publishing: 55] [Article Influence: 12.6] [Reference Citation Analysis]
12 Khoo SY, Brown RM. Orexin/hypocretin based pharmacotherapies for the treatment of addiction: DORA or SORA? CNS Drugs 2014;28:713-30. [PMID: 24942635 DOI: 10.1007/s40263-014-0179-x] [Cited by in Crossref: 42] [Cited by in F6Publishing: 37] [Article Influence: 6.0] [Reference Citation Analysis]
13 Reiter E, Ayoub MA, Pellissier LP, Landomiel F, Musnier A, Tréfier A, Gandia J, De Pascali F, Tahir S, Yvinec R, Bruneau G, Poupon A, Crépieux P. β-arrestin signalling and bias in hormone-responsive GPCRs. Mol Cell Endocrinol 2017;449:28-41. [PMID: 28174117 DOI: 10.1016/j.mce.2017.01.052] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 5.4] [Reference Citation Analysis]